How long do Gliadel wafers last?

After a surgeon operates to remove the cancerous tissue in the brain, he or she implants up to eight dime-sized wafers in the space where the tumor once was. Over the following 2 to 3 weeks, the wafers slowly dissolve, bathing the surrounding cells with the medication.

How long can you live with glioma?

Glioblastoma survival The average survival time is 12-18 months – only 25% of glioblastoma patients survive more than one year, and only 5% of patients survive more than five years.

How long can you live with glioblastoma with treatment?

Patients treated with optimal therapy, including surgical resection, radiation therapy, and chemotherapy, have a median survival of approximately 12 months, with fewer than 25% of patients surviving up to 2 years and fewer than 10% of patients surviving up to 5 years.

What are chemo wafers?

Gliadel wafers are small discs about the size of a 5p coin. The wafers release the chemotherapy drug carmustine as they dissolve. The carmustine in the wafer works by sticking to one of the cancer cell’s DNA strands. The cell can’t then divide into 2 new cells.

When to use Gliadel Wafer in glioblastoma patients?

GLIADEL Wafer is indicated for the treatment of patients with newly-diagnosed high-grade glioma as an adjunct to surgery and radiation. GLIADEL Wafer is also indicated for the treatment of patients with recurrent glioblastoma as an adjunct to surgery.

Can a Gliadel Wafer cause a seizure?

GLIADEL Wafer is also indicated for the treatment of patients with recurrent glioblastoma as an adjunct to surgery. Seizures: Seizures occurred in 37% of patients treated with GLIADEL Wafers for recurrent glioma in the recurrent high-grade glioma trial.

Can a Gliadel Wafer cause a fetus harm?

Embryo-Fetal Toxicity: GLIADEL Wafers can cause fetal harm when administered to a pregnant woman.

How often do seizures occur after Gliadel treatment?

Seizures: Seizures occurred in 37% of patients treated with GLIADEL Wafers for recurrent glioma in the recurrent high-grade glioma trial. New or worsening (treatment emergent) seizures occurred in 20% of patients; 54% of treatment emergent seizures occurred within the first 5 post-operative days.